RT Journal
A1 Castle PE, Fetterman B, Poitras N, Lorey T, Kinney W
T1 SAfety against cervical precancer and cancer following negative human papillomavirus and papanicolaou test results in human immunodeficiency virus–infected women
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2012
FD July 9
VO 172
IS 13
SP 1041
OP 1043
DO 10.1001/archinternmed.2012.1744
UL http://dx.doi.org/10.1001/archinternmed.2012.1744
AB 
Human immunodeficiency virus (HIV) infection, and its clinical manifestation of AIDS, is a known risk factor for cervical precancer2 and cancer,3 and cervical cancer is considered an AIDS-defining malignancy. Current guidelines4 for cervical cancer screening recommend Papanicolaou (Pap) testing twice during the first year after diagnosis of HIV infection and, if the results are normal, annually thereafter. It is unknown whether a negative cotest result might provide similar safety for HIV-infected women as it does for HIV-negative women. Thus, the objective of this analysis was to assess the risk of cervical precancer and cancer following a negative cotest result in HIV-seropositive women 30 years and older.